Ketone Body Compositions for Multi-Factor Lipid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments fail to effectively address elevated serum cholesterol, triglycerides, glucose, homocysteine, inflammation, and hypertension, which contribute to vascular insufficiency and related diseases.
Innovation Solution
Compositions comprising ketone bodies such as D-β-hydroxybutyrate and its derivatives, optionally combined with anti-hypertensive, anti-inflammatory, or glucose-lowering agents, are administered to reduce serum cholesterol, triglyceride, and glucose levels, and manage hypertension through dietary or therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments are used to address elevated serum cholesterol and triglycerides, then some lipid parameters may be partially improved, but multiple vascular risk factors (glucose, homocysteine, inflammation, hypertension) remain unaddressed
Solution Approach 1:
The patent applies universality by using ketone bodies as a multi-functional therapeutic agent that simultaneously addresses multiple vascular risk factors. The composition reduces serum cholesterol, triglycerides, glucose, and homocysteine levels while also reducing inflammatory markers and managing hypertension, making a single treatment versatile against multiple conditions
2Quantity of substance
If dietary fat is restricted to lower cholesterol and triglycerides, then lipid levels improve, but energy intake and patient compliance may be compromised
Solution Approach 1:
The patent uses ketone bodies as an intermediary substance that provides an alternative energy source, allowing patients to follow a low-fat diet more easily. By supplementing with ketone bodies, the diet becomes more palatable and sustainable while still achieving the desired reduction in triglyceride and cholesterol levels
3Adaptability or versatility
If multiple therapeutic agents are combined to address all vascular risk factors, then comprehensive coverage is achieved, but treatment complexity and potential drug interactions increase
Solution Approach 1:
The patent merges multiple therapeutic functions into a single composition containing ketone bodies. This unified approach addresses cholesterol, triglycerides, glucose, homocysteine, inflammation, and hypertension simultaneously, reducing treatment complexity compared to using multiple separate medications
4Quantity of substance
If aggressive lipid-lowering therapy is applied, then serum cholesterol levels decrease rapidly, but risk of side effects and metabolic disturbances increases
Solution Approach 1:
The patent converts the potential harm of aggressive lipid-lowering therapy into benefit by using ketone bodies, which are natural metabolites. These ketone bodies lower cholesterol and triglycerides effectively while simultaneously improving glucose control and reducing inflammation, thereby benefiting multiple systems without the harmful side effects associated with conventional aggressive lipid-lowering medications
Data Source
AI summary
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.